

# PrescQIPP Parkinson's webinar 4:

New developments in the management of Parkinson's

12<sup>th</sup> February 2026

Viv Horton



# Disclosures

- Neurology Academy, Bial
- PDSPN meeting sponsorship from
  - Abbvie
  - Bial
  - Brittanica
  - Ethypharm
  - EverProfile
  - Merz
  - UCB

# Learning outcomes



## Newer treatment options

Apomorphine – sublingual

Levodopa - inhaled



## Research

Ambroxol ASPro-PD


EJS ACT-PD

Prasinezumab

HER – 096

Parkinson's virtual Biotech

?Stem cells



## Not so new - non oral therapies


Apomorphine

Intestinal levodopa +/- entacapone

Subcutaneous foscarnidopa/foslevodopa

Deep brain stimulation

## Current Available UK Parkinson's Medicines 2025



# Inhaled levodopa

- Dose is TWO capsules
  - 66mg delivered
- Single dosage strength
- No dose reduction >65y,
  - limited data >75y
- Contraindicated
  - Non selective MAOBI (monitor BP for selective)
  - Narrow-angle glaucoma.
  - Pheochromocytoma.



# Sublingual apomorphine

- Place film under tongue – should notice 15-30mins after taking
- Need to be able to distinguish 'OFF'
- Test dose 10mg, increase by 5mg increments if needed
- Minimum interval IRL 2 hours
- Max 30mg 5 times daily
- Elderly population included in trials
  - But increased risk of OH
- No data CrCl<30ml/min
- Contraindicated
  - In combination with Ondansetron and other 5HT3 antagonists
  - Dementia/psychosis
  - Hepatic failure
  - Cankers or mouth sores
  - Respiratory depression

**KYNMOBI**<sup>TM</sup>  
(apomorphine HCl) sublingual film



Bial, 2026




**PDSPN**  
Parkinson's Disease  
Specialist Pharmacy Network

**PrescQIPP**  
Funded by the NHS for the NHS



# RESEARCH



Cure Parkinson's 2026

# Ambroxol ASPro-PD


Boost levels of Gcase

Clear waste products

?clear clumps of alphasynuclein and reduce damage to brain cells

ASPro- PD phase 3 trial – 330 participants, 2 years

## ASPro-PD: Ambroxol and Parkinson's



Cure Parkinson's 2026

[Home](#) > [Research](#) > [Research projects](#) > ASPro-PD: Ambroxol and Parkinson's



# PD Frontline

4 years ago

Research news

Genetics and Parkinson's

Share   

pd  
frontline

nts,  
SNCA,  
PRK2,  
LAK,  
LA-  
T11

non


Allele  
frequency

AND Parkinson's isn't 'genetic' in the traditional sense

# What is the MAMS design?

The Multi-Arm Multi-Stage (MAMS) trial design is a flexible and adaptive approach that has improved the speed and efficiency of clinical trials worldwide.

Unlike traditional designs, MAMS allows researchers to test multiple treatment arms at the same time, with the ability to drop treatments that don't show promise and add new ones as they become available.



MAMS designs provide several advantages:

- They can test new treatments faster than traditional trials.
  - They reduce costs, as there is no need to set up a new trial for each new treatment available.
  - They facilitate recruitment as fewer number of participants are required overall.
  - They offer flexibility of dropping and adding new treatments.
- MRC Clinical Trials Unit, UCL, 2026



Parkinson's

adaptive, flexible  
faster than ever



It is led by

You are reading

**Largest-ever Parkinson's disease  
trial opens across UK**

# Prasinezumab

Prasinezumab is a humanized monoclonal antibody  
binds aggregated  $\alpha$ -synuclein and  
inhibits the intercellular spread of pathogenic  $\alpha$ -synuclein  
Potentially protecting neurons and slowing Parkinson's progression






# HER - 096


- Thought to mimic CDNF
- ?neuroprotective
- Completed phase 1 trial (24 patients)
  - Capable of crossing BBB
  - sc injection
- Hopefully phase 2 this year

## How does HER-096 work in the body?

The complex brain pathology underlying degeneration and death of dopamine neurons involves:



Herantis, 2026



# Stem cells

- **PD - loss of dopamine neurones in substantia nigra**
  - Small population – lies deeply in the brain - loss causes motor symptoms
  - Can we grow new neurones – regain dopamine function??
- **Challenges – variable results**
  - Early trials, not very well controlled –
    - Not enough transplanted neurones,
  - COST and scalability
  - Need around 12months immunosuppression for allogenic transplant
    - Brain seems to be different to heart/kidney transplant
- **Encouraging news**
  - Remarkable improvements for some
  - Neurone can survive 20years – but graft takes time to incorporate into brain
  - Reprogramming – stem cell from fibroblast – Shinya Yamanaka
    - Autologous transplant
  - 1 phase 3 trial in US and 1 marketing authorisation in Japan

**Be wary of private clinics offering unproven stem cell therapies**

<https://www.parkinsons.org.uk/about-us/our-views/stem-cell-research>

- Edinburgh Parkinson's lecture 2025
  - <https://www.edinburghparkinsons.org/edinburgh-parkinsons-lecture/>



# Parkinson's UK Virtual Biotech

- International Programme with Parkinson's Foundation
  - Aim – find a cure by collaboration
- Non motor symptoms??
  - TOPHAT – ondansetron for hallucinations
- CHIEF PD - cholinesterase inhibitor to reduce falls
  - results soon?
- PRIME PD – model of care

[https://www.parkinsons.org.uk/sites/default/files/2025-12/VB\\_portfolio\\_Nov\\_2025.pdf](https://www.parkinsons.org.uk/sites/default/files/2025-12/VB_portfolio_Nov_2025.pdf)

## Parkinson's Virtual Biotech


### Parkinson's Virtual Biotech portfolio

November 2025  
Next update: May 2026




# Parkinson's Journey

Non oral therapies



## King's Parkinson's Infusion Pathway:

## Referral to Infusion expert MDT at King's



PD Parkinson's disease; MD movement disorders; MDT multidisciplinary team; NMSQ nonmotor symptoms questionnaire; PKG Parkinson's kinetograph; HADS hospital anxiety and depression scale; MDS-UPDRS movement disorder society unified Parkinson's disease rating scale; NMSS nonmotor symptoms scale; CGIS clinical global impression scale; KPPS King's Parkinson's Pain Scale; ESS Epworth Sleep Scale; MoCa Montreal cognitive assessment; QUIP Questionnaire for Impulsive- Compulsive Disorders in Parkinson's; BDIS Beck's Depression Inventory Scale; PDQ Parkinson's disease Caregiver Burden; PDQ Parkinson's Disease Questionnaire; HY Hoehn and Yahr stage; ECG electrocardiogram; Obs observations; DBS deep brain stimulation; ICD Impulsive compulsive disease; DDS dopamine dysregulation syndrome; EDS excessive daytime sleepiness

# Intestinal levodopa + entacapone

- Intestinal delivery via PEGJ
- Three individually adjusted doses
  - **Morning dose** – usually 5-10ml (100-200mg levodopa) – max 15ml
  - **Continuous rate** – usually during waking hours – 0.7-5.0ml/hour
    - 15-100mg levodopa/hour – max 100ml/day (2000mg levodopa)
    - Gradually increasing levodopa plasma concentration across day
    - Compared to infusion without entacapone
    - Pump programming - 3 continuous rate possible
  - **Bolus** – usually less than 3ml
    - >5 bolus doses - review continuous rate



ResearchGate 2026

Subc

Case s

Meds

Co beneldopa (M  
Rasagiline 1 mg

Co beneldopa (M

Co-beneldopa (f

Opicapone 50m

Botulinum toxin

Table 2. Suggested Produodopa starting hourly infusion rate

LE <sub>16</sub> (LE from all oral LD-containing medications taken over 16-hour awake time (mg))	Suggested Produodopa starting hourly infusion rate (ml/hr) <sup>a</sup> administered over 24 hours
< 400	0.15
400-499	0.15-0.17
500-599	0.17-0.20
600-699	0.20-0.24
700-799	0.24-0.27
800-899	0.27-0.30
900-999	0.30-0.34
1000-1099	0.34-0.37
1100-1199	0.37-0.40
1200-1299	0.40-0.44
1300-1399	0.44-0.47
1400-1499	0.47-0.51
1500-1599	0.51-0.54
1600-1699	0.54-0.57
1700-1799	0.57-0.61

ba



x1

x0.75

5mg

r

h


l

l





# Adaptive Deep Brain stimulation



Newcastle Hospitals 2025



**PDSPN**  
Parkinson's Disease  
Specialist Pharmacy Network

**PrescriPP**  
Funded by the NHS for the NHS

# Latest Findings

Biomarkers linked to Parkinson's progression,  
offer potential for early diagnosis.



# Concluding thoughts



Reasons to be cheerful



Significant challenges



Planning already  
underway



# Questions?